Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis?

Medical Hypotheses

Volumn 69, Issue 5, 2007, Pages 1021-1028

  Stommel, Elijah W ^a   Graber, David ^a   Montanye, Justin ^a   Cohen, Jeffrey A ^a   Harris, Brent T ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; IMIPRAMINE; NEUROLEPTIC AGENT; PHENOTHIAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DEGENERATIVE DISEASE; DEMENTIA; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; PREVALENCE; SCHIZOPHRENIA;

EID: 34548809047     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.02.041     Document Type: Article

References (107)

1. Ziegler L.H. Psychotic and emotional phenomena associated with amyotrophic lateral sclerosis. Arch Neurol Psychiat 24 (1930) 930-936
2. Wechsler I.S., and Davison C. Amyotrophic lateral sclerosis with mental symptoms: a clinicopathological study. Arch Neurol Psychiat 27 (1932) 859-880
3. Friedman A.P., and Freedman D. Amyotrophic lateral sclerosis. J Nerv Ment Dis 111 (1950) 1-18
4. Veit H. Dynamic view of amyotrophic lateral sclerosis. J Nerv Ment Dis 14 (1947) 129-136
5. Brown W.A., and Mueller P.S. Psychological function in individuals with amyotrophic lateral sclerosis (ALS). Psychosom Med 32 (1970) 141-152
6. Peters P.K., Swenson W.M., and Mulder D.W. Is there a characteristic personality profile in amyotrophic lateral sclerosis? A Minnesota multiphasic personality inventory study. Arch Neurol 35 (1978) 321-322
7. Tandan R., and Bradley W.G. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology and ethical issues in management. Ann Neurol 18 (1986) 271-280
8. Garruto R.M., and Yase Y. Neurodegenerative diseases of the Western Pacific: the search for mechanisms of pathogenesis. TINS 9 (1986) 368-374
9. Hudson A.J. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism, another neurological disorders: a review. Brain 104 (1981) 217-247
10. Davison C. Spastic pseudosclerosis (corticopallido-spinal degeneration). Brain 55 (1932) 247-264
11. Jervis G.A., Hurdum H.M., and O'Neil F.J. Presenile psychosis of the Jakob type. Clinico-pathologic study of one case with a review of the literature. Am J Psychiat 99 (1942) 101-109
12. Kurachi M., Koizuni T., Matsubara R., et al. Amyotrophic lateral sclerosis with temporallobe atrophy. Folia Psychiatr Neurol Jpn 33 (1979) 205-215
13. Strong M.J., Lomen-Hoerth C., Caselli R.J., Bigio E.H., and Yang W. Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol 54 Suppl. 5 (2003) S20-S23
14. Ringholz G.M., and Greene S.R. The relationship between amyotrophic lateral sclerosis and frontotemporal dementia. Curr Neurol Neurosci Rep 6 (2006) 387-392
15. Dickson D.W., Horoupian D.S., Thal L.F., et al. Kluver-Bucy syndrome and amyotrophic lateral sclerosis: a case report with biochemistry, morphometrics and Golgi study. Neurology 36 (1986) 1323-1329
16. Rippon G.A., Scarmeas N., Gordon P.H., et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol 63 (2006) 345-352
17. Androp S. Amyotrophic lateral sclerosis with psychosis. Pscyhiatr Q 14 (1940) 118-825
18. Meller C. Amyotrophic lateral sclerosis with psychosis, paranoid type. Minn Med 23 (1940) 858-859
19. Riley W.K., and Tirico J.G. Amyotrophic lateral sclerosis occurring in dementia praecox. M Bull Vet Admin 17 (1940) 180-181
20. Friedlander J.W., and Kesert B.H. The role of psychosis in amyotrophic lateral sclerosis. J Nerv Ment Dis 107 (1948) 243-250
21. Yase Y., Matsumoto N., Azuma K., Nakai Y., and Shiraki H. Amyotrophic lateral sclerosis. Association with schizophrenic symptoms and showing Alzheimer's tangles. Arch Neurol 27 (1972) 118-128
22. Jokelainen M. Amyotrophic lateral sclerosis in Finland. I: an epidemiologic study. Acta Neurol Scand 56 (1977) 185-193
23. Mettler F.A., and Crandell A. Neurologic disorders in psychiatric institutions. J Nerv Ment Dis 128 (1959) 148-159
24. McGuire V., Longstreth Jr. W.T., Koepsell T.D., and van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 47 (1996) 571-573
25. Kurtzke J.F., and Kurland L.T. The epidemiology of neurologic disease. In: Joynt R.J. (Ed). Clinical Neurology (1989), JB Lippincott, Philadelphia
26. Black D.W. Iowa record-linkage study: death rates in psychiatric patients. J Affect Disord 50 (1998) 277-282
27. Nelson L.M., McGuire V., Longstreth Jr. W.T., and Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 151 (2000) 156-163
28. Regier D.A., Farmer M.E., Rae D.S., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 264 (1990) 2511-2518
29. Sugita M., Izuno T., Tatemichi M., and Otahara Y. Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease. J Epidemiol 11 (2001) 87-94
30. Hernan M.A., Takkouche B., Caamano-Isorna F., and Gestal-Otero J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52 (2002) 276-284
31. Allam M.F., Campbell M.J., Hofman A., Del Castillo A.S., and Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 19 (2004) 614-621
32. Kamel F., Umbach D.M., Munsat T.L., Shefner J.M., and Sandler D.P. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 18 (1999) 194-202
33. Howland R.H. Schizophrenia and amyotrophic lateral sclerosis. Compr Psychiat 31 (1990) 327-336
34. Rosen D.R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis [comment]. Nature 362 (1993) 59-62 [erratum appears in Nature 1993 July 22;364(6435):362]
35. Figlewicz D.A., Krizus A., Martinoli M.G., et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 3 (1994) 1757-1761
36. Tomkins J., Usher P., Slade J.Y., et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 9 (1998) 3967-3970
37. Olkowski Z.L. Mutant AP endonuclease in patients with amyotrophic lateral sclerosis. Neuroreport 9 (1998) 239-242
38. Al-Chalabi A., Enayat Z.E., Bakker M.C., et al. Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Lancet 347 (1996) 159-160
39. Gonzalez de Aguilar J.L., Gordon J.W., Rene F., et al. Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiol Dis 7 (2000) 406-415
40. Mu X., He J., Anderson D.W., Trojanowski J.Q., and Springer J.E. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann Neurol 40 (1996) 379-386
41. Rothstein J.D., and Kuncl R.W. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 65 (1995) 643-651
42. Krieger C., Wagey R., and Shaw C. Amyotrophic lateral sclerosis: quantitative autoradiography of [3H]MK-801/NMDA binding sites in spinal cord. Neurosci Lett 159 (1993) 191-194
43. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
44. Olanow C.W. A radical hypothesis for neurodegeneration [comment]. Trends Neurosci 16 (1993) 439-444
45. Zeman S., Lloyd C., Meldrum B., and Leigh P.N. Excitatory amino acids, free radicals and the pathogenesis of motor neuron disease. Neuropathol Appl Neurobiol 20 (1994) 219-231
46. Appel S.H., Smith R.G., Alexianu M.F., Engelhardt J.I., and Stefani E. Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Adv Neurol 68 (1995) 47-57
47. Engelhardt J.I., Siklos L., Komuves L., Smith R.G., and Appel S.H. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 20 (1995) 185-199
48. Smith R.G., and Appel S.H. Molecular approaches to amyotrophic lateral sclerosis. Annu Rev Med 46 (1995) 133-145
49. Demestre M., Pullen A., Orrell R.W., and Orth M. ALS-IgG-induced selective motor neurone apoptosis in rat mixed primary spinal cord cultures. J Neurochem 94 (2005) 268-275
50. Breuer A.C., Lynn M.P., Atkinson M.B., et al. Fast axonal transport in amyotrophic lateral sclerosis: an intra-axonal organelle traffic analysis. Neurology 37 (1987) 738-748
51. Breuer A.C., and Atkinson M.B. Fast axonal transport alterations in amyotrophic lateral sclerosis (ALS) and in parathyroid hormone (PTH)-treated axons. Cell Motil Cytoskel 10 (1988) 321-330
52. Collard J.F., Cote F., and Julien J.P. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis [comment]. Nature 375 (1995) 61-64
53. Sasaki S., and Iwata M. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 47 (1996) 535-540
54. Siesjo B.K. Calcium-mediated processes in neuronal degeneration. Ann NY Acad Sci 747 (1994) 140-161
55. Nicholls D.G. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med 4 (2004) 149-177
56. Choi D.W. Calcium and excitotoxic neuronal injury. Ann NY Acad Sci 747 (1994) 162-171
57. Brorson J.R., Marcuccilli C.J., and Miller R.J. Delayed antagonism of calpain reduces excitotoxicity in cultured neurons. Stroke 26 (1995) 1259-1266 [discussion 1267]
58. 2+ and protein kinase C. Trends Pharmacol Sci 17 (1996) 114-120
59. Strong M.J. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Ther 98 (2003) 379-414
60. Poloni M., Facchetti D., Mai R., et al. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 287 (2000) 211-214
61. Hensley K., Floyd R.A., Gordon B., et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82 (2002) 365-374 [erratum appears in J Neurochem 2002 September;82(6):1570]
62. Yoshihara T., Ishigaki S., Yamamoto M., et al. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80 (2002) 158-167
63. Elliott J.L. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 95 (2001) 172-178
64. Kiaei M., Petri S., Kipiani K., et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26 (2006) 2467-2473
65. Chang Y.C., Tzeng S.F., Yu L., et al. Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobiol Dis (2006)
66. Chiou S.H., Chen S.J., Peng C.H., et al. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 343 (2006) 391-400
67. Sanchez V., Camarero J., Esteban B., Peter M.J., Green A.R., and Colado M.I. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 134 (2001) 46-57
68. Moots R.J., Al-Saffar Z., Hutchinson D., et al. new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 58 (1999) 585-587
69. Arend W.P., and Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38 (1995) 151-160
70. Elliott M.J., Maini R.N., Feldmann M., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
71. Bertini R., Bianchi M., Mengozzi M., and Ghezzi P. Protective effect of chlorpromazine against the lethality of interleukin 1 in adrenalectomized or actinomycin D-sensitized mice. Biochem Biophys Res Commun 165 (1989) 942-946
72. Gadina M., Bertini R., Mengozzi M., Zandalasini M., Mantovani A., and Ghezzi P. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J Exp Med 173 (1991) 1305-1310
73. Bertini R., Garattini S., Delgado R., and Ghezzi P. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice. Immunology 79 (1993) 217-219
74. Mengozzi M., Fantuzzi G., Faggioni R., et al. Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice. Immunology 82 (1994) 207-210
75. Zinetti M., Galli G., Demitri M.T., et al. Chlorpromazine inhibits tumour necrosis factor synthesis and cytotoxicity in vitro. Immunology 86 (1995) 416-421
76. Malberg J.E., and Duman R.S. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neurophyschopharmacol 28 (2003) 1562-1571
77. Wang H.D., Dunnavant F.D., Jarman T., and Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neurophyschopharmacol 29 (2004) 1230-1238
78. Kubera M., Maes M., Holan V., Basta-Kaim A., Roman A., and Shani J. Prolonged desipramine treatment increases the production of interleukin-10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression. J Affect Disord 63 (2001) 171-178
79. Michael-Titus A.T., Bains S., Jeetle J., and Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex-a possible mechanism of neuroprotection in major depression?. Neuroscience 100 (2000) 681-684
80. McKinley E.T., Baranowski T.C., Blavo D.O., Cato C., Doan T.N., and Rubinstein A.L. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res Mol Brain Res 141 (2005) 128-137
81. Hara M.R., Thomas B., Cascio M.B., et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 103 (2006) 3887-3889
82. Nakaso K., Nakamura C., Sato H., Imamura K., Takeshima T., and Nakashima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 339 (2006) 915-922
83. Youdim M.B., Maruyama W., and Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 41 (2005) 369-391
84. +-induced apoptosis. Eur J Neurosci 17 (2003) 1563-1570
85. Kermer P., Liman J., Weishaupt J.H., and Bahr M. Neuronal apoptosis in neurodegenerative diseases: from basic research to clinical application. Neurodegener Dis 1 (2004) 9-19
86. Miller J.B., and Girgenrath M. The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy. Trends Mol Med 12 (2006) 279-286
87. Bursch W., and Ellinger A. Autophagy-a basic mechanism and a potential role for neurodegeneration. Folia Neuropathol 43 (2005) 297-310
88. Yamazaki M., Esumi E., and Nakano I. Is motoneuronal cell death in amyotrophic lateral sclerosis apoptosis?. Neuropathology 25 (2005) 381-387
89. Hervias I., Beal M.F., and Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve 33 (2006) 598-608
90. Lieberman J.A., Tollefson G.D., Charles C., et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiat 62 (2005) 361-370
91. Post A., Holsboer F., and Behl C. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci 18 (1998) 8236-8246
92. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., and Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788 (1998) 215-222
93. Chakos M.H., Shirakawa O., Lieberman J., Lee H., Bilder R., and Tamminga C.A. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiat 44 (1998) 675-684
94. Benes F.M., Paskevich P.A., Davidson J., and Domesick V.B. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res 329 (1985) 265-273
95. Meshul C.K., Janowsky A., Casey D.E., Stallbaumer R.K., and Taylor B. Effect of haloperidol and clozapine on the density of 'perforated' synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology (Berl) 106 (1992) 45-52
96. Konradi C., and Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiat 50 (2001) 729-742
97. Kippin T.E., Kapur S., and van der Kooy D. Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci 25 (2005) 5815-5823
98. Wakade C.G., Mahadik S.P., Waller J.L., and Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69 (2002) 72-79
99. Dalla Libera A., Scutari G., Boscolo R., Rigobello M.P., and Bindoli A. Antioxidant properties of clozapine and related neuroleptics. Free Radiac Res 29 (1998) 151-157
100. Cleren C., Starkov A.A., Calingasan N.Y., Lorenzo B.J., Chen J., and Beal M.F. Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurobiol Dis 20 (2005) 701-708
101. Turner B.J., Rembach A., Spark R., Lopes E.C., and Cheema S.S. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. J Neurosci Res 74 (2003) 605-613
102. Szczudlik A., Tomik B., Slowik A., and Kasprzyk K. Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes. Neurol Neurochir Pol 32 (1998) 821-829
103. Drzyzga L., Obuchowicz E., Marcinowska A., and Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20 (2006) 532-545
104. Pae C.U., Yoon C.H., Kim T.S., et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 6 (2006) 666-671
105. Kowalski J., Blada P., Kucia K., Madej A., and Herman Z.S. Neuroleptics normalize increased release of interleukin-1 β and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 50 (2001) 169-175
106. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., and Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiat 65 (2004) 940-947
107. Muller N., and Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10 (2006) 131-148